Total syntheses and anticholinesterase activities of (3aS)-N(8)- norphysostigmine, (3aS)-N(8)-norphenserine, their antipodal isomers, and other N(8)-substituted analogues

Journal of Medicinal Chemistry

Volumn 40, Issue 18, 1997, Pages 2895-2901

  Yu, Qian Sheng ^a   Pei, Xue Feng ^a   Holloway, Harold W ^a   Greig, Nigel H ^a   Brossi, Arnold ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; N(8) BENZYLESERMETHOLE; N(8) NORPHENSERINE; N(8) NORPHYSOSTIGMINE; UNCLASSIFIED DRUG;

ARTICLE; CHOLINESTERASE INHIBITION; DEMETHYLATION; DRUG PURIFICATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ACETYLCHOLINESTERASE; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; ERYTHROCYTES; HUMANS; INDICATORS AND REAGENTS; ISOMERISM; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; PHYSOSTIGMINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030758320     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970210v     Document Type: Article

References (27)

1. Asthana, A.; Greig, N. H.; Hegedus, L.; Holloway, H. W.; Raffaele, K. C.; Soncrant, T. T. Clinical Pharmacokinetics of Physostigmine in patients with Alzheimer's Disease. Clin. Pharmacol. Ther. 1995, 58, 299-309.
2. Greig, N. H.; Pei, X. F.; Soncrant, T. T.; Ingram, D. K.; Brossi, A. Phenserine and Ring C Hetero-Analogues: Drug Candidates for Treatment of Alzheimer's Disease. Med. Res. Rev. 1995, 15, 3-31.
3. Brossi, A.; Pei, X. F.; Greig, N. H. Phenserine, a Novel Anticholinesterase Related to Physostigmine: Total Synthesis and Biological Properties. Aust. J. Chem. 1996, 49, 171-181.
4. Greig, N. H.; Ingram, D. K.; Wallace, W. C.; Utsuki, T.; Yu, Q. S.; Holloway, H. W.; Pei, X. F.; Haroutunian, V.; Lahiri; Brossi, A.; Soncrant, T. T. Phenserine: a Selective, Long-Acting and Brain-Directed Acetylcholinesterase Inhibitor Affecting Cognition and β-Amyloid Precursor Protein Processing. In Alzheimer's Disease: From Molecular Biology to Therapy; Becker, R., Giacobini, E., Eds.; Birkhauser: Boston, 1996; pp 231-237.
5. Takano, S.; Moriya, M.; Iwabuchi, Y.; Ogasawara, K. A Chiral Route to Both Enationmers of Physostigmine and the First Synthesis of (-)-Norphysostigmine. Chem. Lett. 1990, 109-112.
6. Robinson, B.; Robinson, J. B. The Anti-acetylcholinesterase Activities of The Alkaloids of Physostigma venenosum seeds. J. Pharm. Pharmacol. 1968, 21 (Suppl.), 213s.
7. Testa, B.; Jenner, P. Drug Metabolism: Chemical and Biochemical Aspects; Marcel Dekker Inc.: New York, 1976; Vol. 4.
8. Cozzi, P. G.; Palazzi, C. P.; Potenza, D.; Scolastico, C.; Sun, Y. Total Synthesis of (±)-Pseudophrynamine A. Tetrahedron Lett. 1990, 31, 5661.
9. Sun, W. Y.; Sun, Y.; Tang, Y. C.; Hu, J. Q. Total synthesis of (-)-Pseudophrynamineol. Syn. Lett. 1993, 337.
10. Yu, Q. S.; Brossi, A. Practical Synthesis of Unnatural (+)-Physostigmine and Carbamate Analogues. Heterocycles 1988, 27, 745.
11. Yu, Q. S.; Atack, J. R.; Rapoport, S. I.; Brossi, A. Synthesis and Anticholinesterase Activity of (-)-N1-Norphysostigmine, (-)-Eseramine, and Other N(1)-Substituted Analogues of (-)-Physostigmine. J. Med. Chem. 1988, 31, 2297-2300.
12. Szabo-Pusztay, K.; Szabo, L. A Simple General Method for the Oxidation of Indoles to Oxiindoles. Synthesis 1979, 276.
13. Yu, Q. S.; Luo, W. M.; Li, Y. Q.; Brossi, A. Progress Towards A Practical Total Synthesis of Calabar Alkaloids: Total Synthesis of (-)-Esermethol and (-)-Physovenol Methyl Ether from (3S)-1,3-Dimethyl-3-carboxymethyl-5-methoxyoxindole. Heterocycles 1993, 36, 1279.
14. Katagi, T.; Aoki, M.; Katsu, S.; Kataoka, H.; Hanawa, T. Reductive Rearrangement of Flavone Using Sodium Bis(2-methoxyethoxy)aluminum Dihydride. Chem. Pharm. Bull. 1990, 38, 2256-2258.
15. Pei, X. F.; Bi, S. Reduction of Oxindoles with Sodium Bis(2-methoxyethoxy)aluminum Hydroxide: a Novel Reducing Agent. Heterocycles 1994, 39, 357-360.
16. Pei, X. F.; Yu, Q. S.; Lu, B. Y.; Greig, N. H.; Brossi, A. Practical Total Synthesis of Physostigmine and of Phenserine: A Synopsis. Heterocycles 1996, 42, 229-236.
17. Jackson, A. H.; Smith, A. E. The Protonation of Tryptamine Derivatives in Acidic Media. J. Chem. Soc. 1964, Suppl. 1, 5510.
18. 1-Norphysostigmine and Arylcarbamate Analogues. Med. Chem. Res. 1995, 5, 265-270.
19. Knapp, S.; Wardlow, M. L.; Albert, K.; Wasters, D.; Thal, L. J. Correlation between Plasma Physostigmine Concentration and Percentage of Acetylcholinesterase Inhibition over Time after Controlled-Release Physostigmine in Volunteer Subjects. Drug Metab. Dispos. 1990, 19, 400-404.
20. Brzostowska, M.; He, X. S.; Greig, N. H.; Brossi, A. Phenylcarbamates of (-)-Eseroline, (-)-N1-Noreseroline and (-)-Physovenol: Selective Inhibitors of Acetyl and, or Butrylcholinesterase. Med. Chem. Res. 1992, 2, 238-246.
21. He, X. S.; Greig, N. H.; Brossi, A.; Li, Y. Q.; Yu, Q. S. Thiaphysovenine and Carbamate Analogues: a New Class of Potent Inhibitors of Cholinesterases. Med. Chem. Res. 1992, 2, 227-237.
22. Pei, X. F.; Greig, N. H.; Brossi, A. Preparation and Selective Inhibition of Human Butyrylcholinesterase by N1-Phenylethylnorphysostigmine analogues. Med. Chem. Res. 1995, 5, 455-461.
23. Chatonnet, A.; Lockridge, O. Comparison of Butyrylcholinesterase and Acetylcholinesterase. Biochem. J. 1989, 260, 625-634.
24. Soreq, H.; Zakut, H. Human Cholinesterases and Anticholinesterases; Academic Press: New York, 1993.
25. Massoulie, J.; Pezzementi, L.; Krejci, E.; Vellette, F. M. Molecular and Cellular Biology of Cholinesterase. Prog. Neurobiol. 1993, 41, 31-91.
26. HPLC Chiracel OD column (25 cm × 0.4 cm i.d.; V(0) = 2.497 mL). Bases 6, 7, and 8 were dissolved in ether. Sample inject, 0.1 s; eluent, i-PrOH/hex = 10/90; flow rate, 1.0 mL/min; back pressure, 0.17 kpsi; detector, 254 nm.
27. Robinson, R. In The Alkaloids; Manske, K. H. F., Holmes, H. L., Eds.; Academic Press: New York, 1967; Vol. 10, pp 383-401.